Dr. David Eifrig

Dr. David Eifrig — Profile Update

New Biographical Detail

• Goldman Sachs: Copy explicitly places his MBA/finance background at Goldman Sachs (origin story sequences Wall Street → Columbia pre-med → Goldman Sachs → medicine), sharpening the previously general "investment banker" credential.
• Ophthalmology specifics: His medical-corruption disillusionment centered on an ophthalmologist still performing outdated cataract surgery — cutting the eye wide open rather than using a 2.5mm slit, carrying a ~20% complication rate — which colleagues refused to report.
• Genetics-to-Roche detail reaffirmed: Summer 1996 introductory genetics class; lab work; co-invested company sold to Roche for $125M (tech billed as a Covid-vaccine predecessor).
• Immunotherapy prescience: His 2014 immunotherapy coverage tracks to Merck's Keytruda, which reportedly grew from obscurity to ~$14B in sales by 2020.
• Launch context: Prosperity Investor is framed as his first new service launch in four years, written July 2022 during a bear market. He positions the presentation as his "legacy" and "the most important work I'll ever do."

The "Dream Team" (co-editors introduced)

• Thomas Carroll: Fortune "All-Star Analyst," two-time WSJ "Best on the Street"; Johns Hopkins Bloomberg MPH; 17 years as analyst/managing director at Legg Mason and Stifel ($752B AUM); prior Stansberry work on Investment Advisory and Cannabis Capitalist.
• John Engel: Johns Hopkins MS; engineered proteins/novel therapeutics at Eli Lilly; contributed to Stansberry Venture Technology and Stansberry Innovations Report; credited with a pre-Nobel breakthrough prediction.

How He's Positioned

• Persona reinforced: The MD/MBA "Robin Hood" who fled two corrupt systems (Wall Street, medicine) to serve ordinary retirees — now leading a three-expert healthcare team.
• Signature big idea: The "Health Care Singularity" — AI plus fully digitized health data collapsing the discovery-to-practice gap (arriving ~2025), analogized to Marc Andreessen's "software is eating the world" (now "biology eating the world").
• Method: Dual-track healthcare investing — defensive "forever stocks" (compounding) plus speculative innovators (moonshots); buyout/M&A arbitrage; healthcare as inflation/recession hedge (cited as best inflation hedge across 49 industry groups since 1926, "twice as good as gold").
• Recurring themes: Wealth-and-health inseparability, aging Boomers, genomics/gene-sequencing cost collapse, mRNA, telehealth/wearables, cannabis and psychedelics as forward coverage, healthspan vs. lifespan.

Enriched from 1 additional promo (July 2022 Prosperity Investor launch).

Last enriched by FID from 1 promo(s).

Role: CEO of MarketWise; editor of Retirement Millionaire (also the face guru for True Wealth marketing)

Nickname: The MD/MBA "Robin Hood" (fled Wall Street and medicine to serve retirees)

• MarketWise CEO; MD/MBA with a Goldman Sachs finance background (Wall Street → Columbia pre-med → Goldman → medicine origin arc) — a rare dual credential leaned on heavily for credibility.
• Editor/founder of Retirement Millionaire (founded 2008); also fronts True Wealth marketing where Brett Eversole is the working lead analyst.
• Signature big idea: the "Health Care Singularity" — AI plus digitized health data collapsing discovery-to-practice; dual-track healthcare investing (defensive "forever stocks" plus speculative moonshots).
• Recurring themes: wealth-and-health inseparability, aging Boomers, genomics, mRNA, telehealth/wearables, cannabis and psychedelics as forward coverage.
• Full promo-mined detail in the FinPub Intel block below.

• Goldman Sachs: Copy explicitly places his MBA/finance background at Goldman Sachs (origin story sequences Wall Street → Columbia pre-med → Goldman Sachs → medicine), sharpening the previously general "investment banker" credential.
• Ophthalmology specifics: His medical-corruption disillusionment centered on an ophthalmologist still performing outdated cataract surgery — cutting the eye wide open rather than using a 2.5mm slit, carrying a ~20% complication rate — which colleagues refused to report.
• Genetics-to-Roche detail reaffirmed: Summer 1996 introductory genetics class; lab work; co-invested company sold to Roche for $125M (tech billed as a Covid-vaccine predecessor).
• Immunotherapy prescience: His 2014 immunotherapy coverage tracks to Merck's Keytruda, which reportedly grew from obscurity to ~$14B in sales by 2020.
• Launch context: Prosperity Investor is framed as his first new service launch in four years, written July 2022 during a bear market. He positions the presentation as his "legacy" and "the most important work I'll ever do."

• Thomas Carroll: Fortune "All-Star Analyst," two-time WSJ "Best on the Street"; Johns Hopkins Bloomberg MPH; 17 years as analyst/managing director at Legg Mason and Stifel ($752B AUM); prior Stansberry work on Investment Advisory and Cannabis Capitalist.
• John Engel: Johns Hopkins MS; engineered proteins/novel therapeutics at Eli Lilly; contributed to Stansberry Venture Technology and Stansberry Innovations Report; credited with a pre-Nobel breakthrough prediction.

• Persona reinforced: The MD/MBA "Robin Hood" who fled two corrupt systems (Wall Street, medicine) to serve ordinary retirees — now leading a three-expert healthcare team.
• Signature big idea: The "Health Care Singularity" — AI plus fully digitized health data collapsing the discovery-to-practice gap (arriving ~2025), analogized to Marc Andreessen's "software is eating the world" (now "biology eating the world").
• Method: Dual-track healthcare investing — defensive "forever stocks" (compounding) plus speculative innovators (moonshots); buyout/M&A arbitrage; healthcare as inflation/recession hedge (cited as best inflation hedge across 49 industry groups since 1926, "twice as good as gold").
• Recurring themes: Wealth-and-health inseparability, aging Boomers, genomics/gene-sequencing cost collapse, mRNA, telehealth/wearables, cannabis and psychedelics as forward coverage, healthspan vs. lifespan.

Enriched from 1 additional promo (July 2022 Prosperity Investor launch).

Last enriched by FID from 1 promo(s).